Supporting Inclusion in UK Research
One of the most popular arguments for a “remain” vote amongst the scientific community was the damage that EU funding cuts might do to innovative late-stage biomedical research. Phase 1 trials make up a large share of UK projects, but moving these to clinical research that advances drug discovery in key target populations is a slow process.
However, funding is not much of a problem. The UK could replicate the level of funding of EU programs internal
Unlock Content
Log in to unlock Catalyst access
